PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Listed Company

PACBCIK 0001299130NasdaqAcceleratedLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-546.38M

Total Assets

$784.08M

Equity

$5.35M

Shares Out

310.60M

Op. Cash Flow

$-111.21M

PACB$1.44+3.24% · past yearDBEQ Basic

Daily closing prices

Business

Pacific Biosciences designs, develops, and manufactures advanced long-read DNA sequencing systems and consumables based on proprietary Single-Molecule Real-Time (SMRT) technology. The company offers sequencing instruments (Revio, Vega, Sequel systems), proprietary consumables (SMRT Cells and reagent kits), software, and sequencing services targeting applications in human genomics, plant and animal sciences, infectious disease, oncology, and emerging research fields. Customers include academic institutions, research laboratories, clinical testing facilities, hospitals, pharmaceutical companies, and agricultural organizations globally, served through direct sales forces and distribution partners.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	160	154	201	128	131
Amortization of acquired intangible assets	5	9	2	733,000	306,000
Loss on purchase commitment	4	998,000	3	4	—
Total cost of revenue	114	117	148	79	72
Gross profit	46	37	53	49	59
Research and development	97	135	187	193	113
Sales, general and administrative	141	175	170	161	124
Impairment charges	15	185	0	0	—
Merger-related expenses	0	0	9	0	31
Amortization of acquired intangible assets	365	18	6	0	—
Change in fair value of contingent consideration	−19	−850,000	15	2	1
Total operating expense	600	512	387	356	269
Operating loss	−554	−474	−334	−307	−210
Loss on extinguishment of debt	0	0	−2	0	0
Gain on debt restructuring	0	154	0	0	—
Interest expense	−7	−13	−14	−15	—
Other income, net	15	24	33	8	93,000
Loss before income taxes	−546	−310	−318	−314	−275
Income tax provision (benefit)	318,000	316,000	−11	0	−94
Net loss	−546	−310	−307	−314	−181
Unrealized gain on investments	35,000	203,000	5	−4	−1
Comprehensive loss	−546	−310	−302	−318	−182
Basic (in usd per share)	−1.82	−1.13	−1.21	−1.4	−0.89
Diluted (in usd per share)	−1.82	−1.59	−1.21	−1.4	−0.89
Basic (in shares)	300	274	254	225	204
Diluted (in shares)	300	288	254	225	204

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	64	55	180	325	461
Investments	216	335	452	447	584
Accounts receivable, net	35	28	37	19	24
Inventory, net	49	59	57	50	25
Prepaid expenses and other current assets	11	19	17	10	7
Short-term restricted cash	20,000	690,000	300,000	300,000	500,000
Total current assets	375	496	742	852	1,101
Property and equipment, net	24	31	36	42	33
Operating lease right-of-use assets, net	42	16	33	40	47
Long-term restricted cash	2	2	2	3	5
Intangible assets, net	15	390	457	410	411
Goodwill	318	318	462	410	410
Other long-term assets	9	9	13	11	1
Total assets	784	1,260	1,746	1,767	2,007
Accounts payable	21	17	15	12	11
Accrued expenses	34	23	46	33	36
Deferred revenue, current	16	14	16	30	11
Operating lease liabilities, current	448,000	10	10	9	8
Other liabilities, current	2	3	8	7	6
Total current liabilities	73	66	95	263	72
Deferred revenue, non-current	4	6	6	2	25
Contingent consideration liability, non-current	0	19	20	0	170
Operating lease liabilities, non-current	57	15	32	41	50
Convertible senior notes, net, non-current	645	647	892	897	896
Other liabilities, non-current	0	546,000	751,000	1	3
Total liabilities	779	754	1,045	1,204	1,216
Commitments and contingencies	—	—	—	—	—
Preferred stock	0	0	0	0	—
Common stock	302,000	294,000	268,000	227,000	221,000
Additional paid-in capital	2,700	2,655	2,540	2,100	2,010
Accumulated other comprehensive income	457,000	422,000	219,000	−5	−1
Accumulated deficit	−2,695	−2,149	−1,839	−1,532	−1,218
Total stockholders equity	5	507	701	563	791
Total liabilities and stockholders equity	784	1,260	1,746	1,767	2,007

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	13	14	12	10	7
Amortization of intangible assets	369	27	8	913,000	—
Amortization of right-of-use assets	4	12	7	7	—
Share-based compensation expense	42	71	72	79	73
Merger-related compensation expense	0	0	3	0	0
Accretion of discount and amortization of premium on marketable securities, net	−4	−13	−13	−244,000	4
Inventory provision	10	5	11	6	678,000
Deferred income taxes	−546,000	−205,000	−11	0	—
Other	2	−628,000	1	918,000	—
Accounts receivable, net	−8	9	−18	5	−7
Inventory, net	−1	−8	−14	−34	−13
Prepaid expenses and other assets	9	2	−9	−12	−1
Accounts payable	2	1	206,000	1	6
Accrued expenses	3	−26	13	−4	15
Deferred revenue	101,000	−2	−10	−4	—
Operating lease liabilities	723,000	−12	−9	−8	—
Contingent consideration liability	0	0	−15	0	—
Other liabilities	−1	−5	2	887,000	—
Net cash used in operating activities	−111	−206	−259	−263	−111
Purchase of property and equipment	−3	−6	−9	−17	−6
Purchase of intangible assets	−5	0	0	−179,000	0
Cash paid for purchases of acquired entities, net of cash acquired	0	0	−102,000	0	—
Purchase of investments	−217	−499	−757	−443	−988
Sales of investments	0	35	595,000	0	213
Maturities of investments	340	594	770	576	423
Net cash provided by investing activities	115	124	5	116	−679
Proceeds from issuance of common stock under equity offerings, net of issuance costs	0	0	189	0	32
Proceeds from issuance of common stock from equity plans	3	8	15	11	—
Payment of debt issuance costs	0	0	−7	0	0
Payment of contingent consideration	0	0	−86	0	0
Payments made in conjunction with convertible notes exchange	0	−50	0	0	—
Notes payable principal payoff	0	−490,000	−2	−2	−361,000
Net cash provided by (used in) financing activities	3	−43	109	10	1,170
Net increase (decrease) in cash, cash equivalents, and restricted cash	8	−125	−146	−138	380
Interest paid	8	15	16	14	7
Right-of-use asset and liability additions and modifications	30	—	—	—	3
Convertible notes exchange	0	0	441	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s CIK number?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s SEC CIK number is 0001299130 (1299130). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s SEC filings?

All of PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did PACIFIC BIOSCIENCES OF CALIFORNIA, INC. last report earnings?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001299130-26-000076). This is PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s most recent earnings 8-K?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001299130-26-000076. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s latest earnings 8-K →
Look up any company's CIK number →